Figure 2.

Summary of immunotherapy drugs or treatment strategies for NK/T cell lymphoma and their respective targets. Strategies targeting tumour cell surface antigens or receptors include brentuximab vedotin (CD30) and daratumumab (CD38). Strategies targeting intracellular signalling pathways and the microenvironment include anti-pd1 antibodies (such as pembrolizumab and nivolumab), targeted NF-κB drugs (bortezomib), JAK3 inhibitors (PRN371 and tofacitinib) and autologous T cells targeting LMP2 or LMP1 and LMP2 antigens. These strategies bring hope for this fatal disease.